Literature DB >> 12556568

Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.

Andrew D Krystal1, Richard D Weiner, Margaret D Dean, Virginia H Lindahl, Louis A Tramontozzi, Grace Falcone, C Edward Coffey.   

Abstract

The authors retrospectively compared the seizure duration, ictal EEG, and cognitive side effects of ketamine and methohexital anesthesia with ECT. This comparison was carried out with data from consecutive index ECT treatments that occurred immediately before and after a switch from methohexital to ketamine in 36 patients. Ketamine was well tolerated and prolonged seizure duration overall, but particularly in those who had a seizure duration shorter than 25 seconds with methohexital at the maximum available stimulus intensity. Ketamine also increased midictal EEG slow-wave amplitude. Thus, a switch to ketamine may be useful when it is difficult to elicit a robust seizure. Faster post-treatment reorientation with ketamine may suggest a lower level of associated cognitive side effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556568     DOI: 10.1176/jnp.15.1.27

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  26 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 2.  [Adverse cognitive effects and ECT].

Authors:  Michael Prapotnik; Roger Pycha; Csaba Nemes; Peter König; Armand Hausmann; Andreas Conca
Journal:  Wien Med Wochenschr       Date:  2006-04

Review 3.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

4.  Post-electroconvulsive therapy recovery and reorientation time with methohexital and ketamine: a randomized, longitudinal, crossover design trial.

Authors:  Tony Yen; Mohamad Khafaja; Nicholas Lam; James Crumbacher; Ronald Schrader; John Rask; Mary Billstrand; Jacob Rothfork; Christopher C Abbott
Journal:  J ECT       Date:  2015-03       Impact factor: 3.635

Review 5.  Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder.

Authors:  Sunil Goodwani; Hannah Saternos; Fawaz Alasmari; Youssef Sari
Journal:  Neurosci Biobehav Rev       Date:  2017-02-24       Impact factor: 8.989

6.  A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression.

Authors:  Shona L Ray-Griffith; Lou Ann Eads; Xiaotong Han; Kimberly Golden; Zachary N Stowe
Journal:  J ECT       Date:  2017-12       Impact factor: 3.635

7.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

8.  Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.

Authors:  Murat Altinay; Harish Karne; Amit Anand
Journal:  Psychopharmacol Bull       Date:  2019-02-15

9.  Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.

Authors:  Chadi G Abdallah; Madonna Fasula; Ben Kelmendi; Gerard Sanacora; Robert Ostroff
Journal:  J ECT       Date:  2012-09       Impact factor: 3.635

10.  Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy.

Authors:  Feray Erdil; Zekine Begeç; Gülay Erdoğan Kayhan; Saim Yoloğlu; Mehmet Özcan Ersoy; Mahmut Durmuş
Journal:  J Anesth       Date:  2014-08-02       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.